by user

Category: Documents






Clinical Sciences
Genetic Epidemiology of Spontaneous
Subarachnoid Hemorrhage
Nordic Twin Study
Miikka Korja, MD, PhD; Karri Silventoinen, PhD; Peter McCarron, MD, PhD;
Slobodan Zdravkovic, PhD; Axel Skytthe, PhD; Arto Haapanen, MD, PhD; Ulf de Faire, MD, PhD;
Nancy L. Pedersen, MD, PhD; Kaare Christensen, MD, PhD; Markku Koskenvuo, MD, PhD*;
Jaakko Kaprio, MD, PhD*; the GenomEUtwin Project
Downloaded from http://stroke.ahajournals.org/ by guest on March 29, 2017
Background and Purpose—It would be essential to clinicians, familial aneurysm study groups, and aneurysm families to
understand the genetic basis of subarachnoid hemorrhage (SAH), but there are no large population-based heritability
estimates assessing the relative contribution of genetic and environmental factors to SAH.
Methods—We constructed the largest twin cohort to date, the population-based Nordic Twin Cohort, which comprised
79 644 complete twin pairs of Danish, Finnish, and Swedish origin. The Nordic Twin Cohort was followed up for 6.01
million person-years using nationwide cause-of-death and hospitalization registries.
Results—One hundred eighty-eight fatal and 321 nonfatal SAH cases were recorded in the Nordic Twin Cohort. Thus,
SAH incidence was 8.47 cases per 100 000 follow-up years. Data for pairwise analyses were available for a total of 504
SAH cases, of which 6 were concordant (5 monozygotic and 1 opposite sex) and 492 discordant twin pairs for SAH.
The concordance for SAH in monozygotic twins was 3.1% compared with 0.27% in dizygotic twins, suggesting at most
a modest role for genetic factors in the etiology of SAH. The population-based probability estimate for SAH in dizygotic
siblings of a patient with SAH is 0.54%, and only 1 of 185 full siblings experience familial SAH. The corresponding
risk of SAH in monozygotic twins is 5.9%. Model-fitting, which was based on the comparison of the few monozygotic
and dizygotic pairs, suggested that the estimated heritability of SAH is 41%.
Conclusions—SAH appears to be mainly of nongenetic origin, and familial SAHs can mostly be attributed to
environmental risk factors. (Stroke. 2010;41:2458-2462.)
Key Words: familial 䡲 intracranial aneurysm 䡲 SAH 䡲 twin 䡲 genetics
he incidence of subarachnoid hemorrhage (SAH) of
approximately 7.8 cases per 100 000 person-years in
non-Finnish countries1 together with a 30-day mortality rate
of 40% to 60% ranks SAH among the deadliest vascular
emergencies. Compared with most Western countries, the
risk of SAH is nearly 3 times as high (incidence 21.4 per
100 000 person-years) in Finland,1 the reason for which
remains unclear. Up to 90% of spontaneous SAH cases are
due to rupture of an intracranial aneurysm.2 Important modifiable risk factors for SAH include cigarette smoking (relative risk, 2.2 to 3.1), high blood pressure (relative risk, 2.5 to
2.6), and heavy (ⱖ150 g/week) alcohol consumption (relative
risk, 1.5 to 2.1).3 It has been estimated that the populationattributable risk of cigarette smoking is 20% for SAH,
whereas high blood pressure accounts for 17% and alcohol
abuse for 11% to 21% of SAHs.4
Familial risk is defined as the probability of a healthy
family member being affected by the same disease, which has
already affected at least 1 other family member. Familial risk
of SAH depends on a number of factors, including especially
genetic and environmental factors as well as the number and
ages of relatives at risk. In general, any population-based
heritability estimate value of ⬍50% indicates that environmental variance is greater than genetic variance. Given the
Received April 3, 2010; final revision received July 24, 2010; accepted August 3, 2010.
From the Department of Neurosurgery (M. Korja), Helsinki University Central Hospital, Helsinki, Finland; the Department of Public Health (K.S., M.
Koskenvuo, J.K.), University of Helsinki, Helsinki, Finland; the Department of Epidemiology and Public Health (P.M.), Queen’s University Belfast,
Belfast, UK; the Division of Cardiovascular Epidemiology (S.Z., U.d.F.), Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden;
the Danish Twin Registry (A.S., K.C.), Institute of Public Health, University of Southern Denmark, Odense C, Denmark; the Department of Radiology
(A.H.), Turku University Hospital, Turku, Finland; the Department of Cardiology (U.d.F.), Karolinska University Hospital, Stockholm, Sweden; the
Department of Medical Epidemiology and Biostatistics (N.L.P.), Karolinska Institute, Stockholm, Sweden; the Department of Mental Health (J.K.),
National Institute for Health and Welfare, Helsinki, Finland; and the Institute for Molecular Medicine FIMM (J.K.), Helsinki, Finland.
*These authors share senior authorship.
Correspondence to Miikka Korja, MD, PhD, Department of Neurosurgery, Helsinki University Central Hospital, PO Box 266, FI-00029 HUS, Finland.
E-mail [email protected]
© 2010 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org
DOI: 10.1161/STROKEAHA.110.586420
Korja et al
Table 1.
Genetic Epidemiology of SAH
Characteristics of the Nordic Twin Cohort
Same-Sex Cohort Opposite-Sex Cohort Finnish Cohort Older Cohort Younger Cohort
Year of birth
1870 –1970
1870 –1970
Not applicable
Not applicable
36 (18–95)
49 (36–75)
28 (14–46)
End of the follow-up
No. twin individuals
52 386
27 530
26 326
21 163
32 495
No. complete pairs
26 184
13 765
12 898
10 581
16 236
Females, %
Monozygotic twins, %
Baseline data collection
Mean age in years at baseline (range)
1880 –1957
1886 –1925
*Hospitalized cases of SAH.
Downloaded from http://stroke.ahajournals.org/ by guest on March 29, 2017
relatively low population-based incidence of SAH, it has been
a challenge to estimate the genetic risk of SAH in relatives,
the resolution of which could have significant implications on
prophylactic screening protocols of intracranial aneurysms.
Family history of SAH in first- and second-degree relatives
has been reported to be a significant nonmodifiable risk factor
with a 6.6-fold hazard ratio,5 accounting for 11% of the
population-attributable risk for SAH.4
Large twin cohorts provide a “shortcut” to carry out the
estimation of heritability, defined as the proportion of the
variance on an underlying liability to disease that is due to
genomic effects and of environmentality, the proportion due
to environment. Indeed, twin studies have been described as
“the perfect natural experiment to separate familial resemblance from genetic influence,”6 and large population-based
twin studies can provide the best epidemiological evidence of
familial clustering of any disease. Because of this, in an
attempt to clarify the role of genetics in SAH, we performed
the largest classical twin study to date consisting of Danish,
Finnish, and Swedish population-based twin registers, which
together comprised over 160 000 twin siblings.
Determination of Zygosity
For all 3 national cohorts, zygosity was determined by standardized
questionnaire methods. The questionnaire methods have been validated,11–13 and they correctly classify ⬎95% of twin pairs as
monozygotic (MZ) or dizygotic (DZ).
Data Analysis
Nonfatal and fatal SAHs were recorded during the follow-up time,
which was different for every cohort (Table 1). Twin pairs were
defined as discordant twin pairs for SAH if only 1 twin had an SAH
during the follow-up time regardless of whether the cotwin had died
from another cause. Twin pairs were concordant for SAH if both
twins had an SAH. Sex, zygosity, and age effects on the incidence of
SAH were tested by a Cox proportional hazard model, for which the
follow-up time was calculated from the time point of the baseline
measurement to the date of SAH, death from other causes, emigration, or the end of the follow-up period. The effect of the twin pair
sample design was taken into account using the cluster option of the
Stata statistical package (Version 9.2). The analyses were adjusted
for birth date. Study cohort and sex in the pooled analyses for men
and women were included as a stratum variable, that is, allowing its
own baseline hazard for each group. Proportional hazard assumptions of SAH incidence were not violated for zygosity (P⫽0.60) or
sex (P⫽0.40) when tested using Schoenfeld residuals.
Risk and Genetics of SAH
Subjects and Methods
Study Subjects
Twin cohorts from Denmark, Finland, and Sweden have been
described previously,7–10 and these cohorts comprise the Nordic
Twin Cohort. In brief, Finnish, Swedish, and Danish populationbased cohorts have existed for many decades and they include
virtually all the same-sex twins in the relevant birth cohorts, whereas
the Danish cohort comprises not only same-sex, but also oppositesex twins. The follow-up mortality data were obtained by linkage to
computerized nationwide cause-of-death databases using the unique
personal identifiers assigned to each citizen in each country. Nonfatal SAH cases were derived from national hospital discharge registers, which cover virtually the whole populations of the countries in
the study. The data were available up to the end of 2001 in Denmark
and Sweden and up to the end of 2003 in Finland for fatal SAH. For
nonfatal Finnish SAH cases, the data were updated at the end of
1995. The pooled data comprised 79 664 complete twin pairs and
160 438 individuals including a small number of twins with missing
information on their cotwin. Of all subjects, 51% were women.
Incident cases of SAH as well as all deaths with the underlying cause
of death coded as an SAH or hospitalization for an SAH (the main
cause) were classified as cases. After an SAH (fatal or nonfatal) in a
twin, the median follow-up time for the cotwin was computed as the
time until an SAH (fatal or nonfatal) occurred, emigration, or end of
follow-up. Characteristics of the twin cohorts are presented in Table 1.
Two different estimators of the familial risk of SAH were used. To
estimate the risk that a twin is affected given an affected cotwin,
probandwise concordance was computed by dividing the number of
cases among concordant twin pairs by the total number of cases.14
All cases were ascertained independently, and estimates were computed separately for MZ and DZ pairs. The tetrachoric correlation of
the pairwise (twin 1 versus twin 2 and affected versus unaffected,
2-by-2 table) distribution of cases in MZ and DZ pairs was computed
as an estimate of the underlying, latent liability to SAH based on a
threshold model of the disease.15 Based on these contingency tables
from MZ and DZ tables, standard model-fitting methods for additive
genetic and environmental components of variance were fit using the
Mx, a program for analysis of twin and family data.16,17 All other
analyses were done using the Stata statistical package (Version 9.2).
The total number of twin subjects with SAH in the Nordic
Twin Cohort was 509, but the follow-up data of cotwins were
not available for 5 patients, and they were thus excluded from
all pairwise analyses. The follow-up time was 6.01 million
person-years for all individuals (Table 2). Of 509 twins with
an SAH, 295 (58%) were female and 214 (42%) were male.
SAH incidence in the Nordic Twin Cohort was 8.47 cases per
100 000 follow-up years (26.74, 12.43, 15.56, and 4.27 cases
November 2010
Table 2. Follow-Up Times of the Cohorts, Concordant Twin Pairs for SAH, the Median Age at Diagnosis of
Nonfatal SAH, and the Median Age of Death From SAH Among the 79 664 Twin Pairs
Follow-up time, million
No. fatal SAH cases
No. concordant fatal pairs
No. all SAH cases
No. concordant pairs
Same-Sex Cohort
Opposite-Sex Cohort
Older Cohort
Finnish Cohort
Younger Cohort
Age of death from SAH in
years and IQR†
57.9 (47.5–72.1)
46.0 (41.3–51.6)
56.1 (46.7–68.2)
69.5 (62.8–78.1)
50.0 (39.7–54.3)
Age at diagnosis of all SAHs
in years and IQR†
54.5 (41.8–66.8)
46.0 (38.3–52.3)
51.9 (41.0–64.9)
69.8 (63.5–77.4)
50.0 (41.0–56.9)
7.9 (4.3–13.5)
8.9 (3.8–16.3)
8.6 (5.6–19.0)
12.6 (6.7–18.0)
10.2 (3.8–19.8)
Cotwin follow-up time in
years and IQR†
Downloaded from http://stroke.ahajournals.org/ by guest on March 29, 2017
*Hospitalized cases of SAH.
†Median together with interquartile range (IQR) (ie, lower 关25th percentile兴 and upper 关75th percentile兴 quartiles).
per 100 000 follow-up years in the Finnish, Swedish younger,
Swedish older, and Danish cohorts, respectively; if the
follow-up for the Danish cohort is started after the age of 20
years, the incidence is 7.16 cases per 100 000 follow-up
years; see the Figure). The hazard ratio for women compared
with men was 1.36 (95% CI, 1.10 to 1.69) for SAH incidence,
whereas no difference in age- and sex-adjusted SAH incidence and mortality was found between MZ and DZ twin
individuals in the pooled data (P⫽0.09 and P⫽0.24, respectively). The median age at SAH diagnosis was 53.6 years
(interquartile range, 43.0 to 65.5 years; Table 2).
We identified only 6 twin pairs (12 twin subjects) concordant for SAH, and 5 of these were MZ twin pairs (Table 2).
Patient characteristics for the concordant twin pairs are
depicted in Table 3. In the 6 concordant pairs, the median
time between the onset of SAH in both twin siblings was 3.5
years (range, 0 to 13 years). In comparison, the median
follow-up time for all cotwins after SAH in the other twin
(index case) was nearly 3-fold (9.7 years; interquartile range,
3.5 to 16.3 years; Table 2), which implies that a longer
follow-up would unlikely show more concordant pairs. The
probandwise concordance for all cases was 5.9% in MZ pairs.
Furthermore, the tetrachoric correlation in liability was 0.42
(95% CI, 0.24 to 0.56). For DZ pairs, the probandwise
concordance was 0.54%, and the tetrachoric correlation in
liability was 0.054 (95% CI, 0.0 to 0.26). Of the 492
discordant twin pairs (147 MZ and 345 DZ pairs), 184 (55
MZ and 129 DZ pairs) were discordant for fatal SAH (Table
2). Based on the comparison of the few MZ and DZ pairs,
model-fitting estimate of heritability was 41% (95% CI,
23.7% to 55.5%).
In this first and only large population-based heritability study
assessing the relative contribution of genetic factors to SAH,
we identified only 6 (1.2%) concordant pairs (5 MZ and
opposite sex) of 498 twin pairs with SAH. Only 1 concordant
MZ pair was relatively young at the time of SAH. The
probandwise concordance value of 0.54% for DZ twins
depicts the probability (recurrence risk) of SAH in full (same
father and mother) singleton siblings, who, like DZ twins,
share 50% of their segregating genes. This means that in
families with 1 SAH patient, only 1 of 185 siblings experiences SAH. For MZ twins, who share, in addition to the
genetic sequence, numerous environmental exposures and
experiences, the probandwise concordance value was 5.9%,
which means that every 17th MZ twin will experience an
SAH after an occurrence of an SAH in the cotwin. The MZ
tetrachoric correlation value (42%) implies a moderate size
Table 3.
Figure. Kaplan–Meier survival estimates of the study cohorts.
Patient Characteristics of Concordant Twin Pairs
Age at Death
Age at SAH Diagnosis
Swedish young
M indicates male; F, female.
Korja et al
Downloaded from http://stroke.ahajournals.org/ by guest on March 29, 2017
broad-sense heritability (additive and nonadditive factors),
which can result from additive genetic effects, genetic effects
due to dominance, and genome– environment interaction
effects shared by the twins. If the heritability was due only to
additive genetic effects, the tetrachoric correlation in the DZ
pairs should be 0.21. However, it was considerably lower
(0.054), which implies the presence of effects due to dominance or the combination of genes at multiple loci. Modelfitting based on the comparison of the few MZ and DZ pairs
showed that the estimated heritability was 41% (95% CI,
23.7% to 55.5%), which is very similar to the MZ tetrachoric
correlation value. Previously, we have reported that the
estimated heritability for prostate cancer, colorectal cancer,
and breast cancer is 42%, 35%, and 27%, respectively.10
The strengths of our study include: (1) the populationbased study cohorts with both fatal and nonfatal SAH cases;
(2) the exceptionally large number of twins surveyed; (3) the
satisfactory number of SAH events found among twins; (4)
the reliable estimate of the incidence rate of SAH (8.47 cases
per 100 000 follow-up years) in comparison with previous
reports; 5) the long-term (almost lifetime) prospective
follow-up of unaffected cotwins; 6) the similar centralized
and high-quality cause-of-death and hospitalization registers,
which have been widely used in thousands of previous studies
in Nordic countries; and 7) the presence of the middle-aged
large birth cohort. Because being a sibling of an affected
relative has been reported to increase the risk of having an
aneurysm or SAH more than being a parent or child,18 –20 the
strength of evidence from our study of twin siblings is even
more significant. The fact that twins are siblings of the same
age eliminates the possibility of large phenotypic differences
related to age differences, which complicate the analyses of
genetic studies in singleton siblings and nuclear families. In
addition, the systematic ignoring of extramarital paternity in
family-based studies of heritability may result in some bias,
whereas twin siblings rarely have different fathers.
The major drawbacks include the following: (1) discordant
cotwins were not traced (practically impossible) to check
whether preventive treatments for SAH had been given; (2)
the relatively small proportional representation of young
(⬍25 years of age) individuals in the cohorts; (3) surviving
discordant cotwins were not invited to have an MRI angiogram to estimate the familial prevalence of aneurysms (which
was not the purpose of this study); and (4) register-based
diagnoses may contain errors. It is very unlikely that a
significant number of endo- or exovascular procedures had
been conducted before the rupture of an aneurysm to prevent
a SAH in a discordant cotwin because 62% of the SAH
incidents happened before 1993 when screening of family
members was not a routine procedure nor a recommendation
in Nordic countries. We believe that it is highly unlikely that
the possible ignoring of rare events of SAHs at young ages
may have affected our conclusions drawn.
Due to inevitable difficulties in conducting epidemiological studies on a rare, dichotomous and complex disease trait,
some methodological shortcomings may have influenced
previous interpretations. It has been virtually impossible to
conduct a large enough population-based familial SAH study
containing multiple affected individuals and longitudinal
Genetic Epidemiology of SAH
(several decades of follow-up) family data. Such a study
cannot be done either at present or in the future, because
many unruptured familial and incidental intracranial aneurysms are currently treated. Previous reports suggest that
familial (at least 1 first-degree relative with SAH) occurrence
of SAH is an important nonmodifiable risk factor for
SAH.5,20 –22 Understandably, none of these studies have been
able to control (1) risk factors (ie, confounding factors
including cigarette smoking, high blood pressure, heavy
alcohol consumption) among study and control subjects; (2)
the number of full-sisters and other first-degree family
members of the cases and control subjects when reporting
incidence of SAH in families; and (3) consanguinity among
family members. In accordance with our results, a recent
large population-based (hospital-admitted, mainly nonfatal
index cases) case– control (matched for age and sex, not for
risk factors) study of the risk of familial SAH reported that
only 10 (0.19%) of 5282 hospital-admitted patients with SAH
have ⱖ2 first-degree relatives with an SAH (ie, ⱖ3 patients
with SAH in the family), and 156 (2.95%) patients with SAH
have 1 affected first-degree relative in the family.23 In total,
only 166 (3.14%) of 5282 patients with SAH have ⱖ1
affected first-degree family members.23 The OR (not relative
risk) of familial SAH for individuals with ⱖ1 affected
first-degree relatives was 2.28 when compared with age- and
sex-matched control subjects (ie, no adjustment for, for
example, confounding risk factors), of which 1.41% had SAH
cases in the family.23 If the lifetime relative risk of SAH of a
family member was 2-fold or even 15-fold higher than in the
general population, for which the lifetime risk has been
estimated to be 0.7%,23 the absolute lifetime risk of SAH
would be 1.4% and 10.5%, respectively. The recent
population-based data suggest an absolute lifetime risk of
SAH of 26% (OR, 51.0) for individuals with ⱖ2 first-degree
relatives with SAH.23 This very high lifetime risk estimate
surely warrants screening programs for these rare SAH
Our results with the heritability estimate of 41% suggest
that there is a moderate role for genetic factors in the etiology
of SAH, whereas environmental factors play a significant role
in SAH susceptibility at the population level. This relatively
low heritability estimate for a complex trait suggests that very
large genomewide association studies, similar to recent studies of intracranial aneurysms,24,25 or whole genome linkage
studies are necessary to identify genomic variants and candidate genes underlying the risk for SAH. Alternatively, genetic
studies should focus on identifying rare variants in the
families with multiple affected members.
In brief, our results together with the previous results23
suggest that a positive family history accounts for, at the
most, only a small percentage of SAHs, not for 11% of the
population-attributable risk for SAH.4 Of these rare familial
SAH cases, possibly only a minority is due to the clustering
of susceptibility genes. It is conceivable that familial clustering of confounding risk factors (eg, cigarette smoking, high
blood pressure, and heavy alcohol consumption) makes a
significant contribution to previously reported incidence rates
November 2010
of familial SAHs. On the basis of current evidence, screening
of familial aneurysms may be warranted at least for first-degree
family members with ⱖ2 SAHs in the family and to a monozygotic sibling of a MZ twin with a positive history of SAH.
We thank Professors Juha Hernesniemi and Mika Niemelä from the
Helsinki University Central Hospital (Helsinki, Finland) and Professor Aarno Palotie from the Wellcome Trust Sanger Institute (Cambridge, UK), the Finnish Genome Center (Helsinki, Finland), and the
Broad Institute of MIT and Harvard (Cambridge, Mass) for reviewing primary versions of the manuscript.
Sources of Funding
Downloaded from http://stroke.ahajournals.org/ by guest on March 29, 2017
This work was supported by a personal grant from the Pro Humanitate Foundation to M.Korja. The Finnish Twin Cohort was supported
by a grant from the Academy of Finland Centre of Excellence in
Complex Disease Genetics to J.K. The Swedish Twin Registry is
supported by grants from the Swedish Research Council and the
Ministry of Higher Education. The funders had no role in the design
and conduct of the study; in collection, management, analysis, and
interpretation of the data; or in preparation, review, or approval of
the manuscript.
1. Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid
hemorrhage: role of region, year, and rate of computed tomography:
a meta-analysis. Stroke. 1996;27:625– 629.
2. Ronkainen A, Hernesniemi J. Subarachnoid haemorrhage of unknown
aetiology. Acta Neurochir (Wien). 1992;119:29 –34.
3. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J,
Anderson CS. Risk factors for subarachnoid hemorrhage: an updated
systematic review of epidemiological studies. Stroke. 2005;36:
4. Ruigrok YM, Buskens E, Rinkel GJ. Attributable risk of common and
rare determinants of subarachnoid hemorrhage. Stroke. 2001;32:
5. Bromberg JE, Rinkel GJ, Algra A, Greebe P, van Duyn CM, Hasan D,
Limburg M, ter Berg HW, Wijdicks EF, van Gijn J. Subarachnoid
haemorrhage in first and second degree relatives of patients with subarachnoid haemorrhage. BMJ. 1995;311:288 –289.
6. Martin N, Boomsma D, Machin G. A twin-pronged attack on complex
traits. Nat Genet. 1997;17:387–392.
7. Skytthe A, Kyvik K, Holm NV, Vaupel JW, Christensen K. The Danish
twin registry: 127 birth cohorts of twins. Twin Res. 2002;5:352–357.
8. Kaprio J, Koskenvuo M. Genetic and environmental factors in complex
diseases: the older Finnish Twin Cohort. Twin Res. 2002;5:358 –365.
9. Lichtenstein P, De Faire U, Floderus B, Svartengren M, Svedberg P,
Pedersen NL. The Swedish Twin Registry: a unique resource for clinical,
epidemiological and genetic studies. J Intern Med. 2002;252:184 –205.
10. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo
M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable
factors in the causation of cancer—analyses of cohorts of twins from
Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78 – 85.
Cederlof R, Friberg L, Jonsson E, Kaij L. Studies on similarity diagnosis
in twins with the aid of mailed questionnaires. Acta Genet Stat Med.
1961;11:338 –362.
Hauge M, Harvald B, Fischer M, Gotlieb-Jensen K, Juel-Nielsen N,
Raebild I, Shapiro R, Videbech T. The Danish Twin Register. Acta Genet
Med Gemellol (Roma). 1968;17:315–332.
Sarna S, Kaprio J, Sistonen P, Koskenvuo M. Diagnosis of twin zygosity
by mailed questionnaire. Hum Hered. 1978;28:241–254.
Allen G. Models of proband concordance rates for twins in a clinical
series. Acta Genet Med Gemellol (Roma). 1970;19:146 –149.
Falconer DS, Mackay TFC. Introduction to Quantitative Genetics.
Harlow: Longman; 1996.
Neale MC, Boker SM, Xie G, Maes HH. Mx: Statistical Modeling.
Richmond, VA: Virginia Commonwealth University; 2002.
Neale MC, Cardon LR. Methodology for Genetic Studies of Twins and
Families. Dordrecht, The Netherlands: Kluwer Academic Publishers;
MARS Study Group. Risks and benefits of screening for intracranial
aneurysms in first-degree relatives of patients with sporadic subarachnoid
hemorrhage. N Engl J Med. 1999;341:1344 –1350.
Raaymakers TW. Aneurysms in relatives of patients with subarachnoid
hemorrhage: frequency and risk factors. MARS Study Group. Magnetic
resonance angiography in relatives of patients with subarachnoid hemorrhage. Neurology. 1999;53:982–988.
Schievink WI, Schaid DJ, Michels VV, Piepgras DG. Familial aneurysmal
subarachnoid hemorrhage: a community-based study. J Neurosurg. 1995;83:
Gaist D, Vaeth M, Tsiropoulos I, Christensen K, Corder E, Olsen J,
Sorensen HT. Risk of subarachnoid haemorrhage in first degree relatives
of patients with subarachnoid haemorrhage: follow up study based on
national registries in Denmark. BMJ. 2000;320:141–145.
Teasdale GM, Wardlaw JM, White PM, Murray G, Teasdale EM, Easton
V. The familial risk of subarachnoid haemorrhage. Brain. 2005;128:
Bor AS, Rinkel GJ, Adami J, Koffijberg H, Ekbom A, Buskens E,
Blomqvist P, Granath F. Risk of subarachnoid haemorrhage according to
number of affected relatives: a population based case– control study.
Brain. 2008;131:2662–2665.
Bilguvar K, Yasuno K, Niemela M, Ruigrok YM, von Und Zu Fraunberg
M, van Duijn CM, van den Berg LH, Mane S, Mason CE, Choi M, Gaal
E, Bayri Y, Kolb L, Arlier Z, Ravuri S, Ronkainen A, Tajima A, Laakso
A, Hata A, Kasuya H, Koivisto T, Rinne J, Ohman J, Breteler MM,
Wijmenga C, State MW, Rinkel GJ, Hernesniemi J, Jaaskelainen JE,
Palotie A, Inoue I, Lifton RP, Gunel M. Susceptibility loci for intracranial
aneurysm in European and Japanese populations. Nat Genet. 2008;40:
Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G,
Simon M, Krex D, Arlier Z, Nayak N, Ruigrok YM, Niemela M, Tajima
A, von und zu Fraunberg M, Doczi T, Wirjatijasa F, Hata A, Blasco J,
Oszvald A, Kasuya H, Zilani G, Schoch B, Singh P, Stuer C, Risselada R,
Beck J, Sola T, Ricciardi F, Aromaa A, Illig T, Schreiber S, van Duijn
CM, van den Berg LH, Perret C, Proust C, Roder C, Ozturk AK, Gaal E,
Berg D, Geisen C, Friedrich CM, Summers P, Frangi AF, State MW,
Wichmann HE, Breteler MM, Wijmenga C, Mane S, Peltonen L, Elio V,
Sturkenboom MC, Lawford P, Byrne J, Macho J, Sandalcioglu EI, Meyer
B, Raabe A, Steinmetz H, Rufenacht D, Jaaskelainen JE, Hernesniemi J,
Rinkel GJ, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y,
Lifton RP, Gunel M. Genome-wide association study of intracranial
aneurysm identifies three new risk loci. Nat Genet. 42:420 – 425.
Genetic Epidemiology of Spontaneous Subarachnoid Hemorrhage: Nordic Twin Study
Miikka Korja, Karri Silventoinen, Peter McCarron, Slobodan Zdravkovic, Axel Skytthe, Arto
Haapanen, Ulf de Faire, Nancy L. Pedersen, Kaare Christensen, Markku Koskenvuo, Jaakko
Kaprio and the GenomEUtwin Project
Downloaded from http://stroke.ahajournals.org/ by guest on March 29, 2017
Stroke. 2010;41:2458-2462; originally published online September 16, 2010;
doi: 10.1161/STROKEAHA.110.586420
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628
The online version of this article, along with updated information and services, is located on the
World Wide Web at:
Data Supplement (unedited) at:
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.
Once the online version of the published article for which permission is being requested is located, click
Request Permissions in the middle column of the Web page under Services. Further information about this
process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
Subscriptions: Information about subscribing to Stroke is online at:
自然発症くも膜下出血の遺伝疫学 — 北欧双生児研究
Genetic Epidemiology of Spontaneous Subarachnoid Hemorrhageke ― Nordic Twin Study
Miikka Korja, MD, PhD1; Karri Silventoinen, PhD2; Peter McCarron, MD, PhD3; Slobodan Zdravkovic,
PhD4; Axel Skytthe, PhD5; Arto Haapanen, MD, PhD6; Ulf de Faire, MD, PhD4,7; Nancy L. Pedersen, MD,
PhD8; Kaare Christensen, MD, PhD5; Markku Koskenvuo, MD, PhD2; Jaakko Kaprio, MD, PhD2,9,10; the
GenomEUtwin Project
Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland; 2 Department of Public Health, University of Helsinki,
Helsinki, Finland; 3 Department of Epidemiology and Public Health, Queen’s University Belfast, Belfast, UK; 4 Division of Cardiovascular
Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden; 5 Danish Twin Registry, Institute of Public Health,
University of Southern Denmark, Odense C, Denmark; 6 Department of Radiology, Turku University Hospital, Turku, Finland; 7 Department of
Cardiology, Karolinska University Hospital, Stockholm, Sweden; 8 Department of Medical Epidemiology and Biostatistics, Karolinska Institute,
Stockholm, Sweden; 9 Department of Mental Health, National Institute for Health and Welfare, Helsinki, Finland; 10 Institute for Molecular
Medicine FIMM, Helsinki, Finland.
瘤の家系に属する人々にとって,くも膜下出血( SAH )の
しかし,一般住民を対象に SAH に対する遺伝的要因と環
ンド,スウェーデンで生まれたすべての双生児 79,644 組
国死因登録簿および入院登録簿を用いて,合計 601 万人・
結果:北欧双生児コホートから致死的 SAH 188 例および
非致死的 SAH 321 例の記録が得られた。100,000 追跡調
査年あたりの SAH 発症率は 8.47 件であった。合計 504
組の SAH 症例についてペア解析のデータが得られ,この
うち 6 組はともに SAH を発症し( 5 組は一卵性,1 組は異
性の二卵性 ),492 組は一方のみが SAH を発症していた。
SAH の一致率は,一卵性双生児が 3.1%,二卵性双生児が
0.27%で,SAH 発症における遺伝的要因の役割はさほど
値に基づき推定した患者の同胞の SAH 発症確率は 0.54%
であり,同胞 185 例のうち 1 例が家族性 SAH を発症す
リスク値は 5.9%であった。このように少数の一卵性双生
SAH の遺伝率は 41%と推測された。
結論:SAH は主に遺伝以外の原因によって生じるようで
あり,家族性 SAH は主として環境危険因子に起因してい
Stroke 2010; 41: 2458-2462
表 3 ともに SAH を発症した双生児の患者特性
1 =デンマーク
2 =フィンランド
3 =スウェーデン若年層
4 =スウェーデン高齢層
コホート =1
コホート =3
stroke5 4.indb 17
コホート =2
コホート =4
本研究コホートの Kaplan‒Meier 生存推定値。
11.4.1 11:20:34 AM
Fly UP